BMO Capital Markets upgraded shares of Stryker (NYSE:SYK) to a market perform rating in a research note published on Tuesday, The Fly reports. BMO Capital Markets currently has $163.00 target price on the medical technology company’s stock.

A number of other research firms have also recently issued reports on SYK. Cowen set a $166.00 target price on Stryker and gave the company a buy rating in a research note on Sunday, October 29th. Needham & Company LLC reissued a hold rating on shares of Stryker in a report on Friday, November 3rd. ValuEngine lowered Stryker from a buy rating to a hold rating in a report on Friday, December 1st. SunTrust Banks reissued a buy rating and set a $161.00 price target on shares of Stryker in a report on Friday, November 17th. Finally, Oppenheimer set a $156.00 price target on Stryker and gave the company a hold rating in a report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $153.19.

Shares of Stryker (NYSE:SYK) opened at $154.25 on Tuesday. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $56,637.12, a price-to-earnings ratio of 23.98, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78. Stryker has a one year low of $116.50 and a one year high of $160.62.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period last year, the business posted $1.39 earnings per share. equities research analysts anticipate that Stryker will post 6.47 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be paid a $0.47 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.22%. This is a boost from Stryker’s previous quarterly dividend of $0.43. Stryker’s dividend payout ratio (DPR) is currently 36.32%.

In related news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the transaction, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in SYK. Acrospire Investment Management LLC acquired a new stake in Stryker during the 2nd quarter worth about $111,000. Motco lifted its holdings in shares of Stryker by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after buying an additional 278 shares during the last quarter. San Francisco Sentry Investment Group CA lifted its holdings in shares of Stryker by 47.8% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after buying an additional 325 shares during the last quarter. Bruderman Asset Management LLC acquired a new stake in shares of Stryker during the 2nd quarter valued at about $150,000. Finally, James Investment Research Inc. acquired a new stake in shares of Stryker during the 2nd quarter valued at about $155,000. Hedge funds and other institutional investors own 74.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/16/bmo-capital-markets-upgrades-stryker-syk-to-market-perform.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

The Fly

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Stock Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related stocks with our FREE daily email newsletter.